Solarfuture
2 months ago
https://transkript.de/artikel/2024/gute-datenlage-immatics-kann-direkt-in-phase-iii-gehen/
Good data situation: immatics can go directly into Phase III
Tübingen-based Immatics NV published updated Phase Ib clinical data on ACTengine® IMA203, which allow for a more in-depth analysis compared to the last data update in May 2024. The data on progression-free survival (PFS) and overall survival (OS) are so convincing that the company can proceed directly with an approval-ready Phase III study on this basis. And Immatics is using the tailwind to place new shares for $150 million.
The data from the ongoing Phase 1b study have been eagerly awaited and will only be presented tomorrow by Dr. Martin Wermke at the Society for Melanoma Research Congress 2024. However, the Tübingen-based company Immatics NV is making it public earlier. The observation of significant tumor shrinkage and a lasting response in combination with meaningful results on progression-free survival and overall survival after a single treatment with ACTengine® IMA203, which Dr. Martin Wermke, coordinating investigator of the TCR-T study, will present there, are simply too impressive to keep quiet any longer.
"These results now confirm the therapeutic potential of IMA203 in this patient population, all of whom have exhausted multiple lines of systemic treatment. They demonstrate the impact IMA203 can have in patients with metastatic melanoma and provide a strong rationale for accelerating late-stage clinical development of this product candidate," said Wermke.
And that is the second important part of the advance announcement before the congress presentation: With the complete study data from Phase I, Immatics can go straight into a phase III study that is relevant for approval after consultation with the FDA. Recruitment will start soon, but the company expects that it will take around a year until enough study participants have been found, and then another year until the crucial data packages can be viewed in an interim analysis.
The Type D meeting with the US Food and Drug Administration (FDA) took place at the end of September. The study design for SUPRAME (Phase III) was discussed, in which IMA203, which targets PRAME, will be investigated in 360 HLA-A*02:01-positive patients with inoperable or metastatic melanoma in the second line or later (2L+) who were previously treated with a checkpoint inhibitor.
"We are excited about the clinical data as they confirm our belief in the durability and long-term efficacy of ACTengine® IMA203, as demonstrated by the favorable median progression-free survival of patients in the dose expansion cohort. I would like to highlight that a subset of 12 of the 26 patients had a reduction in tumor lesion size of more than 50% and a median PFS of 13.4 months," said Dr. Cedrik Britten, Chief Medical Officer at Immatics. "We believe that the presentation of this data set, coupled with our recent meeting with the FDA, which resulted in a pivotal study design with progression-free survival as the primary endpoint for full approval, positions us to significantly advance the development of IMA203."
The Tübingen-based cell therapy company is taking advantage of the tailwind and today announced the start of a subscribed public offering for its common shares. The volume is planned to reach 150 million US dollars, but this also depends a little on the current stock market situation. However, the data could also lead to increased interest.
© |transkript.de
Georg Kääb
October 10, 2024
FACT-MASTER
2 months ago
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST
Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)
Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial
Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmed
IMA203 continues to maintain a favorable tolerability profile in patients in Phase 1a and Phase 1b treated across all dose levels
IMA203 demonstrates a confirmed objective response rate of 54% with median duration of response of 12.1 months in Phase 1b
Median PFS is 6 months, comparing favorably to the IMA203 Phase 1a dose escalation median PFS of 2.6 months; patients with deep responses show median PFS of more than one year; median OS not reached
Phase 3 trial, “SUPRAME,” will enroll 360 patients with unresectable or metastatic melanoma post treatment with a checkpoint inhibitor (2L+) and will randomize patients 1:1 for treatment with IMA203 or investigator’s choice
Primary endpoint for full approval will be median PFS, which constitutes the fastest pathway to registration in this patient population
SUPRAME Phase 3 trial is on track to commence in December 2024; enrollment forecasted to be completed in 2026 with a pre-specified interim analysis planned for early 2026
Conference call and webcast can be accessed here
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in melanoma patients and provided an update on SUPRAME, the upcoming Phase 3 trial to evaluate IMA203 in metastatic melanoma patients.
The data from the ongoing Phase 1b trial will be presented on Friday, October 11, 2024, by Martin Wermke, M.D., during Plenary Session 1, Developmental Immunotherapy (Cellular Immunotherapy, Vaccines, & New Checkpoints) at the Society for Melanoma Research Congress 2024. The IMA203 data slides are accessible in the ‘Events & Presentations’ section of the Investor & Media section of the Company’s website. The conference presentation will include additional patient cases.
“Observing significant tumor shrinkage and durable responses combined with meaningful progression-free survival and overall survival outcomes after a single treatment with ACTengine® IMA203 in this patient population that have all exhausted multiple lines of systemic treatments illustrates the impact IMA203 can have on metastatic melanoma patients,” said Martin Wermke, M.D., Coordinating Investigator of the ACTengine® IMA203 TCR-T trial. “These results now affirm the therapeutic potential of IMA203 and provide a strong rationale for the expedited late-stage clinical development of this product candidate.”
“We are enthusiastic about the clinical data as they confirm our conviction in the durability and long-term efficacy of ACTengine® IMA203, demonstrated by the favorable median progression-free survival for patients in the dose expansion cohort. I would like to highlight that a subgroup of 12 out of 26 patients showed more than 50% reduction of tumor lesions and a median PFS of 13.4 months,” said Cedrik Britten, M.D., Chief Medical Officer at Immatics. “We believe the presentation of this data set in conjunction with our recent meeting with the FDA, which has resulted in a pivotal trial design with progression-free survival as the primary endpoint for full approval, positions us to advance the development of IMA203 in the second-line or later metastatic melanoma setting.”
Patient Population and Clinical Data Summary - ACTengine® IMA203 Monotherapy Phase 1b Trial
Patient population: Heavily pretreated metastatic melanoma patients
As of August 23, 2024, 28 heavily pretreated patients with metastatic melanoma were treated at the recommended Phase 2 dose (RP2D, 1 to 10 billion total TCR-T cells) with IMA203 during the Phase 1b dose expansion part of the clinical trial. The treated patient population is composed of patients with a median of 2 lines of prior systemic treatments, consisting of cutaneous melanoma patients (N=13), uveal melanoma patients (N=12), mucosal melanoma patients (N=2) and a patient with melanoma of unknown primary (N=1).
Safety: Favorable tolerability profile demonstrated across all dose levels in Phase 1a and Phase 1b
IMA203 monotherapy has maintained a favorable tolerability profile with no treatment-related Grade 5 adverse events in the safety population (N=701 Phase 1a and Phase 1b patients across all dose levels and all tumor types), even at doses up to ~10x109 TCR-T cells.
The most frequent adverse events were expected cytopenias (Grade 1 – 4) associated with lymphodepletion as well as mostly mild to moderate cytokine release syndrome (CRS). Some patients infrequently experienced ICANS (Grade 1: 6%, Grade 2: 4%, Grade 3: 4%).
The full IMA203 monotherapy tolerability profile is also generally consistent with that observed in the Phase 1b melanoma subset.
Anti-tumor activity and durability: Durable objective responses in melanoma patients at RP2D3
This data update adds substantial maturity to the most recent data update from May 2024 (data cut-off on April 25, 2024). The median follow-up for the median duration of response for this analysis was 9.3 months compared to 3.5 months in May 2024.
All melanoma patients in Phase 1b
(N=282,3)
Cutaneous melanoma patients in Phase 1b (N=133)
Confirmed Objective Response Rate
54% (14/26)
54% (7/13)
Objective Response Rate
62% (16/26)
62% (8/13)
Disease Control Rate
92% (24/26)
92% (12/13)
Tumor Shrinkage
88% (23/26)
85% (11/13)
Median Duration of Response
12.1 months
12.1 months
Median Progression-Free Survival
6.0 months
6.1 months
Median Overall Survival
Not reached
15.9 months
Progression-free survival (PFS) and overall survival (OS): Significant shift in PFS and OS between Phase 1a dose escalation to Phase 1b dose expansion in melanoma patients
Manufacturing improvements were implemented prior to the Phase 1b part of the trial to enhance key features of IMA203. As a result, all patients in dose expansion were treated with an updated version of IMA203 that includes a T cell enrichment process using monocyte depletion (negative selection) or CD8/CD4 positive selection.
The data presented today demonstrate a significant positive shift in median PFS and median OS between melanoma patients treated during Phase 1a and patients treated in Phase 1b.
Phase 1b dose expansion melanoma patients
(N=28)
Phase 1a dose escalation melanoma patients
(N=11)
Median Progression-Free Survival
6.0 months
2.6 months
Median Overall Survival
Not reached
6.3 months
In addition, approximately half of all patients in the Phase 1b trial have a deep response (>50% tumor reduction). This subgroup of patients was observed to have a median PFS of more than one year, while patients with <50% tumor reduction (including patients with tumor size increase) were still observed with a more than 2 times longer median PFS compared to patients treated in dose escalation with suboptimal doses.
Translational data: IMA203 T cell dose and T cell exposure are associated with clinical responses
Translational data from patients across Phase 1a and Phase 1b indicate that IMA203 T cells rapidly engrafted in all patients after a single dose and show a persistence of more than two years. Three associations/correlations were observed demonstrating high consistency of dose exposure, biological data and clinical outcome in all patients treated with IMA203 for which samples were available (N=65):
IMA203 T cell dose is significantly associated with confirmed clinical responses (p=0.02),
IMA203 T cell dose is correlated with T cell peak level (cmax, r=0.84, p=1.6x10-18),
IMA203 T cell peak level (cmax, p=0.05) and T cell exposure (AUC0-28d, p=0.05) are associated with confirmed clinical responses.
Development Path and Manufacturing for ACTengine® IMA203 Monotherapy
On September 24, 2024, Immatics completed a Type D meeting with the U.S. Food and Drug Administration (FDA) to confirm RP2D and the CMC package as well as discuss the trial design for SUPRAME, the planned registration-enabling Phase 3 randomized-controlled clinical trial for IMA203. Written post-meeting minutes from the FDA have been received.
The Phase 3 trial will evaluate IMA203 targeting PRAME in 360 HLA-A*02:01-positive patients with second-line or later (2L+) unresectable or metastatic melanoma who have received prior treatment with a checkpoint inhibitor. Patients will be randomized 1:1 for IMA203 or investigator’s choice of selected approved treatments in the 2L+ setting.
Based on the Company’s discussions with the FDA, the primary endpoint for full approval will be median PFS. Given the expected PFS of 2-3 months4 in this patient population, as well as the PFS of 6 months observed in the data from the IMA203 Phase 1b trial, the Company has determined that utilizing median PFS as the primary endpoint is the fastest pathway to seeking full approval and presents a more attractive commercial positioning as compared to objective response rate (ORR). Secondary endpoints for the trial will include ORR, safety, duration of response, no overall survival detriment and patient-reported outcomes. A pre-specified interim analysis is planned for early 2026.
The SUPRAME Phase 3 trial is planned to run globally with sites in the United States and Europe with the initial goal of seeking Biologics License Application (BLA) approval in the United States. On October 2, 2024, Immatics also completed a meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority, and determined the same trial design for conducting the clinical trial in Germany.
The Phase 3 trial is on track to commence in December 2024 and patient enrollment is forecasted to be completed in 2026. The Company aims to submit a BLA in early 2027 for full approval.
Immatics’ late-stage clinical cell therapy development is supported by its differentiated manufacturing related to timeline, capabilities and facilities. ACTengine® IMA203 cell therapy products are manufactured within 7 days, followed by a 7-day QC release testing at a success rate of >95% to reach the target dose. The Company has also completed construction of a ~100,000 square foot R&D and GMP manufacturing facility with a modular design for efficient and cost-effective scalability intended to serve early-stage and registration-enabling trials, as well as commercial supply. The new site is expected to start GMP manufacturing of cell therapy products in early 2025. Meanwhile, the existing GMP facility, which is run in collaboration with UT Health, will remain active until YE 2025.
Immatics Conference Call and Webcast
Immatics will host a conference call and webcast today, October 10, 2024, at 9:00 am EDT/ 3:00 pm CEST to discuss the clinical data.
A replay of the webcast will be made available shortly after the conclusion of the call and archived on the Immatics website for at least 90 days.
About ACTengine® IMA203 and Target PRAME
ACTengine® IMA203 is Immatics’ most advanced TCR-based autologous cell therapy that is directed against an HLA-A*02-presented (human leukocyte antigen) peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently expressed in a large variety of solid cancers. PRAME is homogeneously and specifically expressed in tumor tissue and Immatics’ PRAME peptide is present at a high copy number per tumor cell. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform, XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for ACTengine® IMA203.
ACTengine® IMA203 TCR-T is currently being evaluated as a monotherapy in a Phase 1 clinical trial in patients with solid tumors expressing PRAME, such as cutaneous melanoma. An IMA203 registration-enabling randomized controlled Phase 3 trial, “SUPRAME,” is planned to commence in December 2024.
ACTengine® IMA203 TCR-T is also currently being evaluated in Phase 1 IMA203CD8 (GEN2) monotherapy, where IMA203 engineered T cells are co-transduced with a CD8aß co-receptor.
- END -
https://finance.yahoo.com/news/immatics-announces-updated-phase-1b-103000214.html
Solarfuture
2 months ago
Immatics () has received a new Buy rating, initiated by Piper Sandler analyst, .
Joseph Catanzaro has given his Buy rating due to a combination of factors surrounding Immatics’ potential in the biotechnology sector. He identifies the company’s PRAME-targeting portfolio as having extensive utility across various solid tumors. Catanzaro is particularly impressed by Immatics’ lead program, IMA203, which he believes could offer superior cell therapy for post-PD-1 melanoma based on scenario modeling that indicates competitive durability and potential for registrational development. Furthermore, he sees substantial opportunity for Immatics’ cell therapy portfolio beyond melanoma, particularly with IMA203CD8, which could show meaningful clinical activity in ovarian, endometrial, and lung cancers. Catanzaro’s outlook suggests that Immatics’ pipeline could lead to blockbuster therapies, with data expected in the next 6-18 months that could further reduce investment risks.
The positive rating also stems from validation of Immatics’ proprietary platforms, XPRESIDENT and XCEPTOR, which are starting to show clinical validation in their abilities to identify relevant peptide targets and generate highly active TCRs. These platforms have positioned Immatics to build a pipeline capable of developing first-in-class or best-in-class therapies for solid tumor indications. The report also highlights the competitive profile of the IMA203 program in post-PD-1 melanoma, noting its potential for best-in-indication response rates, competitive durability, and favorable safety profile. Lastly, Catanzaro emphasizes the potential of Immatics’ PRAME-targeting portfolio outside of melanoma, supported by strong evidence from clinical datasets and the enhanced efficacy observed with the incorporation of the CD8 co-receptor. Despite the inherent risks in clinical, regulatory, and commercial areas, Catanzaro’s analysis suggests a strong Buy recommendation for Immatics.
https://www.tipranks.com/news/blurbs/immatics-promising-pipeline-and-buy-recommendation-a-comprehensive-analysis-by-joseph-catanzaro?mod=mw_quote_news
Solarfuture
2 months ago
That's fine!
Yes, think we have good chance to see some nice weeks coming up...
Interesting article:
At the European Cancer Congress ESMO in Barcelona, Tübingen-based immatics NV did not present any new data on advanced T-cell therapy developments, but rather early data on the bispecific approach of a T-cell receptor against MAGEA4/8. The fact that the partner Bristol Myers Squibb is backing out of this previously collaborative development is only reported as a side note.
The many good news reports on advances in the treatment of cancer at the ESMO Congress in Barcelona in mid-September have given some companies like BioNTech a real boost, with their share prices soaring in just a few days. Tübingen-based immatics NV, on the other hand, did not choose the more advanced development of the so-called ACT engine, which is currently being evaluated in phase Ib either on its own or in combination with a CD8 binding site, as its presentation topic. This study is to continue with an increased dosage and will then be presented at another conference a little later in the year.
In contrast, Immatics' previous, preclinical approach to a bispecific T cell engaging receptor (TCER®) candidate, IMA401, was presented at the current conference. This is derived from a technology for the production of next-generation bispecific TCR molecules with an extended half-life. The molecules were developed to "maximize efficacy while minimizing toxicities," according to the company. The proprietary format, consisting of a high-affinity TCR domain against the tumor target and a low-affinity T cell recruiter that binds to the T cell, offers a more convenient dosing regimen for the patient than if such molecular capabilities had to be administered as individual active ingredients in combination.
Dr. Martin Wermke from the University Hospital Dresden presented the first clinical data of IMA401 (directed against the tumor antigen MAGEA4/8), which provided information on the safety, pharmacokinetics and antitumor activity of TCER IMA401 from the phase I dose escalation. These data show initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy. The patient population includes 35 heavily pretreated patients with a total of 16 different solid tumor types; the dose escalation is now ongoing.
Only 29% was considered to be an objective response rate (ORR), or even 25% in the confirmed ORR (cORR). Nevertheless, a disease control rate (DCR) of 53% and a tumor shrinkage rate of 53% were shown in the "efficacy population" (i.e. those who responded). In addition, a "sustained partial response" of up to 13+ months and a deeper response (with tumor shrinkage of ≥50%) were shown in very different tumors, which is now being used as a justification for continuing and further increasing the dosage.
It was announced in passing that the previous development partner Bristol Myers Squibb is withdrawing from this sub-project of a broader development partnership (which was reported in the news a few months ago when it was converted into a shareholder ) and that immatics is giving back all rights. The stock market remained quiet, probably because immatics is currently extremely well financed with a good 530 million euros in the bank to take the next development steps on its own. The presentations from the adoptive, modified cell therapy development track will now receive much more attention, because the next approval-relevant studies are due to be carried out there after good data. Things remain exciting in Tübingen.
© |transkript.de
Georg Käab
17. September 2024
https://transkript.de/artikel/2024/hoch-und-tief-bei-immatics/
FACT-MASTER
3 months ago
IMTX: Presentation on Phase 1a/1b IMA401 tomorrow at ESMO/24
Remember IMA401 is in collaboration with BMS ( https://immatics.com/our-pipeline/)
ESMO Abstract
https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/show/session/232#presentation-abstract-895832222418
Abstract
Background
T cell-engaging bispecifics are designed to redirect T cells to cancer antigens. IMA401 is a next-gen T cell engaging receptor (TCER®) combining a high-affinity TCR domain against an HLA-A*02:01-presented MAGEA4/8 peptide, a low-affinity T cell-recruiting antibody and an Fc part for half-life extension. The target peptide exhibits a >5-fold higher density compared to the MAGEA4-derived peptide targeted by other bispecifics or cell therapies.
Methods
This ongoing Phase 1a/1b first-in-human clinical trial evaluates IMA401 in patients (pts) with recurrent/refractory solid tumors. HLA-A*02:01+ and MAGEA4/8+ pts received initially QW then Q2W iv. IMA401 infusions. Primary objectives: MTD and/or RP2D. Secondary objectives: safety, tolerability, PK, initial anti-tumor activity.
Results
As of April 1, 2024, 25 heavily pretreated cancer pts received IMA401 across the first dose levels (DL1-7, 6.6µg-2.5mg). IMA401 showed manageable tolerability with most common (≥30%) treatment-related adverse events being transient lymphopenia (G1-4) and CRS (G1/2). High-grade (G3/4) neutropenia observed at DL7 did not reoccur after the introduction of dexamethasone pre-treatment. MTD/RP2D was not reached and dose escalation is ongoing. Median terminal half-life was 15.0 days. 55% (11/20) of efficacy-evaluable pts treated in the escalation phase, including initial low MABEL-based starting DLs, achieved disease control (SD/PR). Among these were pts with ovarian cancer, sqNSCLC, gastric cancer, HNSCC, melanoma, and neuroendocrine carcinoma. 45% (9/20) of the pts showed shrinkage of target lesions (median -21.7%), including 3 pts with durable confirmed PRs at 4+, 10+ and 11+ months after first infusion.
Conclusions
IMA401 was well tolerated and its single-agent anti-tumor activity was demonstrated by durable objective responses and disease control. The prolonged half-life prompted a switch to treatment every 2 weeks already during dose escalation. The data of this ongoing Phase 1 dose escalation trial provide first clinical PoC for the next-gen half-life extended TCER® format and its potential in multiple solid tumors.
Clinical trial identification
NCT05359445.
Legal entity responsible for the study
Immatics Biotechnologies GmbH.
FACT-MASTER
3 months ago
Agree.
Another presentation just announced for the 21st International Congress of the Society for Melanoma Research on October 11/24.
Looks like a possible update coming on IMA203. If i recall correctly IMTX had RMAT designation for IMA203 - this could get very interesting, imo
https://finance.yahoo.com/news/immatics-announces-upcoming-oral-presentation-110000681.html
Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research.
Oral presentation
Date / Time: October 11, 2024 / 8:00 – 8:20 am Central Daylight Time
Session: Plenary Session 1 – Developmental Immunotherapy (Cellular Immunotherapy, Vaccines, and New Checkpoints)
Title: ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma – Clinical Update
Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany)
About IMA203
ACTengine® IMA203 T cells is an autologous T cell product with a genetically modified, pairing-enhanced TCR directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). This peptide is frequently expressed in a large variety of solid cancers, thereby supporting the program’s potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform, XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine® IMA203.
ACTengine® IMA203 TCR-T is currently being evaluated in a Phase 1 trial as IMA203 monotherapy, and as a second-generation IMA203CD8 (GEN2) monotherapy, where IMA203-engineered T cells are co-transduced with a CD8aß co-receptor, thereby leveraging the power of both CD4+ and CD8+ T cells. As previously reported, IMA203 in combination with an immune checkpoint inhibitor has been deprioritized.
FACT-MASTER
5 months ago
IMTX: Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
( this looks like a highly important presentation, imo)
https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-concept clinical data for its next-generation, half-life extended TCR Bispecific molecule, TCER® IMA401 (MAGEA4/8), will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 on Monday, September 16, 2024 at 11:25 CEST.
Full abstracts will be available on the ESMO website on Monday, September 9, 2024, at 00:05 CEST.
Oral presentation
Date / Time: September 16, 2024 / 11:25 CEST
Session: Investigational Immunotherapy
Title: Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation
Presenting author: Martin Wermke, MD (University Hospital Dresden, Germany)
Room: Granada Auditorium - Hall 6
About IMA401
IMA401 is Immatics’ most advanced TCER® molecule that targets an HLA-A*02-presented (human leukocyte antigen) peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT® and is presented at a 5-fold higher copy number per tumor cell than the MAGEA4 peptide targeted in other clinical trials. Following preclinical proof-of-concept data, including complete remissions of transplanted human-derived tumors in xenograft mouse models, the Phase 1 trial investigates IMA401 in patients with tumors of high MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma (sqNSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types.
About TCER®
Immatics’ next-generation half-life extended TCER® molecules are antibody-like “off-the-shelf” biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER® molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells’ intrinsic specificity. Immatics proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER® format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, low-affinity T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient’s T cells to the tumor to attack the cancer cells. With a low-affinity recruiter aiming for optimized biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER® are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER® format consists of an Fc-part conferring half-life extension, stability, and manufacturability. TCER® are “off-the-shelf” biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and provide the opportunity to reach a large patient population without the need for specialized medical centers.
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
https://finance.yahoo.com/news/immatics-announces-upcoming-oral-presentation-130000787.html
Level up your trading with our powerful tools and real-time insights all in one place.
jondoeuk
1 week ago
Monksdream
1 month ago
Hot Features
Premium
